Back to top
more

Regeneron Pharmaceuticals (REGN)

(Real Time Quote from BATS)

$887.92 USD

887.92
204,027

-18.62 (-2.05%)

Updated Apr 25, 2024 12:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study

by Zacks Equity Research

ASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with eczema, who have previously been treated with Dupixent but did not achieve an adequate response.

Why Is Exelixis (EXEL) Up 10.9% Since Last Earnings Report?

by Zacks Equity Research

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

EXEL vs. REGN: Which Stock Is the Better Value Option?

by Zacks Equity Research

EXEL vs. REGN: Which Stock Is the Better Value Option?

Bayer (BAYRY) Q4 Earnings Top, Crop Science Unit Drives Revenues

by Zacks Equity Research

Bayer (BAYRY) beats earnings estimates in the fourth quarter of 2023, primarily driven by increased sales of Crop Science and Pharmaceuticals products.

Intellia (NTLA) Beats on Q4 Earnings, Provides Pipeline Update

by Zacks Equity Research

Intellia's (NTLA) earnings beat estimates in the fourth quarter while the company reports negative revenues. Management provides developmental and regulatory updates on its key pipeline candidates.

The Zacks Analyst Blog Highlights Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron

by Zacks Equity Research

Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron are included in this Analyst Blog.

Biotech Stock Roundup: MRNA's Q4 Results, RAPT Down on Study Results & Other Updates

by Zacks Equity Research

Earnings from Moderna (MRNA) and pipeline update from RAPT are in focus in the biotech sector.

Roche's (RHHBY) Xolair Gets Approval for Food Allergies

by Zacks Equity Research

Roche (RHHBY) obtains FDA approval for Xolair for the treatment of children and adults with one or more food allergies.

Alnylam (ALNY) Q4 Loss Narrower Than Expected, Stock Dips 10%

by Zacks Equity Research

Alnylam (ALNY) reports mixed fourth-quarter 2023 results, as earnings beat estimates, while revenues miss the same. The stock of the company falls 10%.

Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat

by Zacks Equity Research

Ultragenyx (RARE) reports better-than-expected fourth-quarter 2023 results, beating both earnings and revenue estimates, driven by strong sales trends of Crysvita and Dojolvi.

EXEL or REGN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EXEL vs. REGN: Which Stock Is the Better Value Option?

Regeneron (REGN) Q4 Earnings & Sales Top, Eylea Sales Decline

by Zacks Equity Research

Regeneron (REGN) beats earnings and sales estimates in fourth-quarter 2023, fueled by Dupixent. However, sales of the lead drug, Eylea, continue to fall.

Regeneron (REGN) Reports Q4 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Regeneron (REGN) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Regeneron (REGN) delivered earnings and revenue surprises of 13.71% and 5.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Roche (RHHBY) 2023 Earnings Miss, COVID-19 Product Sales Down

by Zacks Equity Research

Roche (RHHBY) misses earnings and sales estimates in 2023 due to a significant decline in COVID-19-test sales. Currency rate fluctuations also impact results.

Sanofi (SNY) Misses on Q4 Earnings and Sales, Stock Down

by Zacks Equity Research

Sanofi (SNY) misses fourth-quarter estimates for earnings and sales. It maintains 2024 earnings growth guidance.

Biotech Stock Roundup: GSK's Q4 Results, VRTX Gains on Update, TSVT Up on REGN Deal

by Zacks Equity Research

Earnings from GSK and other updates from 2seventy bio (TSVT) were in focus in the biotech sector.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

Regeneron (REGN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when Regeneron (REGN) reports its fourth-quarter 2023 results.

2seventy bio (TSVT) Divests R&D Assets to Regeneron, Stock Up

by Zacks Equity Research

2seventy bio (TSVT) inks an asset purchase agreement with Regeneron to sell its oncology and autoimmune pipeline to the latter.

Novartis (NVS) Q4 Earnings Miss on Higher Costs, Sales Lag

by Zacks Equity Research

Novartis' (NVS) earnings and sales miss estimates in the fourth quarter. The outlook for 2024 does not look promising as well.

Pfizer (PFE) Q4 Earnings Top, Revenues Miss on COVID Sales Slump

by Zacks Equity Research

Pfizer (PFE) reports mixed fourth-quarter 2023 results. It re-affirms its 2024 sales and earnings guidance provided in December 2023.

Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gear Up for Regeneron (REGN) Q4 Earnings: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.

Fate Therapeutics (FATE) Soars 25.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Fate Therapeutics (FATE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.